Biopharma

COVID-19: Fighting a global pandemic with innovation

In this episode of Ideas to Innovation, Clarivate life sciences and healthcare experts reflect on partnering with pharma to combat the pandemic. Listen now.   COVID-19 has presented an enormous global challenge, requiring an unprecedented level of engagement by stakeholders across pharma, research and policy. While SARS-CoV-2 emerged as a novel virus to which humans […]

Pharmacy benefit reform in Medicaid addresses drug transparency

Clarivate U.S. market access experts discuss recent Medicaid policy changes in some states meant to control drug costs and increase transparency. Read more. In recent years, state governments began to notice rising costs of drugs and hidden charges associated with them. As state and federal governments contribute to a large portion of Medicaid expenses, they […]

Top oncology breakthroughs shared at ESMO 2021

Clarivate oncology experts share major takeaways from ESMO and their expected impact on the treatment landscape and patients. As part of our Drugs to Watch™ series, which reviews therapies expected to have significant impact on healthcare markets, Clarivate oncology experts sifted through the more than 2,800 abstracts that were accepted for presentation at the ESMO […]

Healthcare consolidation paves way for care delivery changes

Clarivate U.S. market access experts discuss on recent mergers, cause of these mergers and their impact on the healthcare system. Read more.  Changes in the U.S. healthcare industry, many of which were prompted by the pandemic, are driving consolidations to cover gaps in care and stabilize revenue streams. Payers are engaging in non-traditional mergers, such as the announcement by UnitedHealth Group’s Optum unit to buy Change Healthcare to strengthen its analytics, technology and revenue cycle management capabilities. Payers […]

Best practices for university-healthcare partnerships: Lessons from Oxford

In this episode of Conversations in Healthcare, Mike Ward speaks with Dr. Phil Clare, Deputy Director, Research Services, Knowledge Exchange and Engagement at the University of Oxford, about the process of translating academic research into new healthcare products and services.     Mike Ward: A key component of that ecosystem is the fundamental research that’s […]

Type 2 diabetes in Mainland China: Shifting treatment patterns

Mainland China has gone through a series of regulatory and reimbursement reforms in recent years in an effort to keep pace with its dynamic economic and demographic landscape. Clarivate market assessment expert Karan Verma discusses the role of these reforms in Mainland China’s type 2 diabetes market and how they could broaden access to innovative […]

Three key trends in regulatory approvals of new medicines

A new study by the Centre for Innovation in Regulatory Science (CIRS) has shown that despite regulatory convergence over the last 20 years, there are still differences in approval times across global regulatory agencies. The following article summarizes key findings from the latest CIRS R&D Briefing, New drug approvals in six major authorities 2011-2020. Three […]

Volume-Based Procurement in Mainland China: Key trends and planning future strategies

Mainland China has gone through a series of regulatory and reimbursement reforms in recent years in an effort to keep pace with its dynamic economic and demographic landscape. Clarivate expert Karan Verma discusses how the Volume-Based Procurement program is transforming the generics landscape, increasing patient access and prompting manufactures to rethink strategies.   Remodeling Mainland […]